Life Scientist > Molecular Biology

More than meets the eye as Affymetrix chases transcription

25 February, 2003 by Melissa Trudinger

With the increasing recognition of the importance of non-coding RNA in regulation and control of gene expression, it now appears there is much more to the genome than meets the eye.


Proteomics facility launches its latest phase

20 February, 2003 by Iain Scott

The Australian Proteome Analysis Facility (APAF) today launched the latest phase of its development, unveiling a new logo and plans to become self-sufficient within the next five years.


The world is getting smaller for Australian nanotech ventures

19 February, 2003 by Melissa Trudinger

As a nation, Australia has often lagged behind bigger and better-funded countries when it comes to seizing on a new technology and taking it to new places. But with the emerging nanotechnology industry, Australia is finding itself in a position of relative strength, despite our size.


Genomics: doing Moore with less

17 February, 2003 by Graeme O'Neill

Genomics is experiencing its own manifestation of computing technology's Moore's law of cost and efficiency, says Prof Richard Gibbs: the volume of sequence data is increasing by around 10-fold every year as sequencing costs continue to plummet.


DNA shuffling in the genetics game

13 February, 2003 by Graeme O'Neill

Dr Willem (Pim) Stemmer has spent the past decade demonstrating, in the most graphic manner possible, the value of biodiversity, and the existence of a massive genetic treasure trove in nature, far greater than the sum of its individual components.


Nobel headcount grows for Genetics Congress

13 February, 2003 by Graeme O'Neill

The Nobel winner count for July's International Congress of Genetics has risen to eight, with confirmation that Sir John Sulston will be joining fellow 2002 Medicine laureates Sir Sydney Brenner and Prof Robert Horvitz in Melbourne.


Revolution in genetics tipped as brave new world of RNA revealed

11 February, 2003 by Graeme O'Neill

A new branch of genetics is being born. It might legitimately be called junk science, but Prof John Mattick has dubbed it 'Rnomics'... and it's the stuff of revolution.


New supercomputers for Queensland facility

30 January, 2003 by Pete Young

Quadrupled throughput capacity at the Queensland Parallel Supercomputer Foundation (QPSF) is part of an upsurge in high-performance computing resources becoming available to life science-oriented researchers.


Gene therapy shouldn't be abandoned: Australian researcher

15 January, 2003 by Graeme O'Neill

The US Food and Drug Administration this week suspended about 30 gene-therapy trials in the US after another 'boy in a bubble' patient in a French gene-therapy trial developed leukaemia. But Australian gene-therapy expert Assoc Prof Panos Ioannou said the setback did not mean gene therapy should be abandoned, or that it posed unacceptable risks.


CSIRO maths guru quits for private sector

20 December, 2002 by Pete Young

CSIRO is losing the services of one of the country's premier biostatisticians, Dr Mervyn Thomas, who is leaving to launch his own consultancy in the private sector.


New SA fund to help early-stage companies

13 December, 2002 by Melissa Trudinger

A new biotech funding initiative in South Australia, the BioCatalyst Program Fund, will provide grants of up to $250,000 to start up and early stage companies to help them commercialise their ideas.


Genetic research joins centre of excellence roster

13 December, 2002 by Pete Young

Genetic research will occupy the focus of two of eight new centres of excellence which together will share almost $90 million in Federal funding over the next five years.


Gradipore touts US growth after gel range expansion

11 December, 2002 by Iain Scott

Sydney-based company Gradipore is predicting increased sales in its main US market after launching a new range of electrophoresis gels.


Data visualisation: See what you're doing?

11 December, 2002 by Pete Young

The growing sophistication of data visualisation applications has been a boon for pharmaceutical and biotech researchers across the life and chemical sciences spectrum. Visualisation platforms help computational chemists to model molecules in drug discovery environments and genomic researchers to stitch useable information together from a confusing tangle of data held in different gene sequence databases.


Commercialisation: When institutes go to market

10 December, 2002 by David Binning

Advances in techniques for growing neurons, stem cell research, genetics, proteomics and massively improved capabilities in imaging are opening up previously undreamed-of avenues to treat sufferers of everything from epilepsy, stroke, chronic pain, multiple sclerosis, paralysis and psychosis.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd